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Abstract
Background Providing proof of presence of Shiga toxin–producing E. coli (STEC) infection forms the basis for differentiating
STEC-hemolytic uremic syndrome (HUS) and atypical HUS. As the gold standard to diagnose STEC-HUS has limitations, using
ELISA to detect serum antibodies against STEC lipopolysaccharides (LPS) has proven additional value. Yet, conventional LPS-
ELISA has drawbacks, most importantly presence of cross-reactivity due to the conserved lipid A part of LPS. The newly
described glyco-iELISA tackles this issue by using modified LPS that eliminates the lipid A part. Here, the incremental value of
glyco-iELISA compared to LPS-ELISA is assessed.
Methods A retrospective study was performed including all pediatric patients (n = 51) presenting with a clinical pattern of STEC-
HUS between 1990 and 2014 in our hospital. Subsequently, the diagnostic value of glyco-iELISAwas evaluated in a retrospec-
tive nationwide study (n = 264) of patients with thrombotic microangiopathy (TMA). LPS- and glyco-iELISAwere performed to
detect IgM against STEC serotype O157. Both serological tests were compared with each other and with fecal diagnostics.
Results Glyco-iELISA is highly sensitive and has no cross-reactivity. In the single-center cohort, fecal diagnostics, LPS-ELISA,
and glyco-iELISA identified STEC O157 infection in 43%, 65%, and 78% of patients, respectively. Combining glyco-iELISA
with fecal diagnostics, STEC infection due to O157 was detected in 89% of patients. In the nationwide cohort, 19 additional
patients (8%) were diagnosed with STEC-HUS by glyco-iELISA.
Conclusion This study shows that using glyco-iELISA to detect IgM against STEC serotype O157 has clear benefit compared to
conventional LPS-ELISA, contributing to optimal diagnostics in STEC-HUS.
Keywords Shiga toxin–producing E. coli . Hemolytic uremic syndrome . Serology . Glycoproteins
Introduction
Providing proof of the presence of Shiga toxin (Stx)–produc-
ing Escherichia coli (STEC) infection forms the basis for dif-
ferentiation between STEC-hemolytic uremic syndrome
(HUS) and atypical HUS (aHUS). Both are important causes
to bear in mind in patients who present with signs indicative of
thrombotic microangiopathy (TMA), hemolytic anemia,
thrombocytopenia, and acute kidney injury. The current gold
standard to detect STEC infection involves fecal examination
by culture and detection of Stx-encoding genes by polymerase
chain reaction (PCR) [1–3]. However, detection of STEC in
the feces is limited due to the natural course of the disease.
Furthermore, due to low inoculums, detection of STEC in the
feces becomes increasingly difficult as the disease progresses.
Despite new and upcoming fecal diagnostic techniques, such
as molecular serotyping, sole use of fecal diagnostics is not yet
sufficient in establishing STEC infection [4].
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As the gold standard diagnostic for STEC-HUS has various
limitations, the use of enzyme-linked immunosorbent assay
(ELISA) to detect serum antibodies against the lipopolysac-
charides (LPS; LPS-ELISA) of STEC has proven its value [2,
5, 6]. As previously shown, the combination of fecal diagnos-
tics with LPS-ELISA to detect immunoglobulin M (IgM)
against STEC serotype O157 clearly has an added value in
the detection of STEC infection as the cause of HUS [6]. Yet,
the conventional LPS-ELISA, in which plates are coated with
purified LPS, has various drawbacks. The most important
limitation is the presence of cross-reactivity caused by the
conserved lipid A part of the LPS molecule [5, 7, 8]. The
LPS structure consists of a lipid A part, an outer and inner
core, and an O-antigen, of which the latter has the highest
immunogenic activity. Since the lipid A is also present in other
strains of STEC, and even other gram-negative bacteria, this
could lead to cross-reactivity and ultimately lead to false-
positive results [7, 9, 10]. Although O157 antigen remains
the most prevalent serotype associated with STEC-HUS, other
non-O157 strains (such as O26, O103, O104, O111, O55) are
increasingly detected. Differentiation between the different
STEC serotypes is important considering the variation in clin-
ical presentation, course of the disease per serotype, and the
epidemiological consequences [2, 6, 11].
To tackle the aforementioned issues, the group of J.E.
Ugalde and D.J. Comerci exploited a new ELISA tech-
nique—indirect glycoprotein-based ELISA (glyco-
iELISA)—for the detection of STEC infection in HUS pa-
tients [8, 11]. This glyco-iELISA takes advantage of a bacte-
rial glycoengineering technology to develop and produce re-
combinant serotype-specific glycoproteins consisting of the
O157 polysaccharide attached to the protein carrier acceptor
AcrA (O157-Acr), in the absence of the lipid A part. As
shown by Melli et al., the glyco-iELISAwas able to diagnose
STEC in HUS patients, even in cases where fecal diagnostics
failed [11]. More importantly, due to the absence of the lipid A
structure of LPS in the glycoprotein constructs used in this
assay, potential cross-reactivity is counteracted. Thus, glyco-
iELISA appears to be a highly sensitive and specific assay [8].
Up until now, differentiation between STEC-HUS and
aHUS remains a clinical conundrum, which can be tackled
with the introduction of the glyco-iELISA [12]. Although
STEC-HUS and aHUS require a completely different treat-
ment approach, and clinical outcome is divergent, discrimina-
tion in the acute phase remains challenging [13, 14]. Whereas
diarrhea is the clinical hallmark of STEC-HUS, in up to 30%
of the patients with aHUS, a gastrointestinal infection has
been found [13, 14]. Moreover, aHUS is treated with one of
the world’s most expensive orphan drugs: the humanized
monoclonal antibody, eculizumab [15]. In comparison, the
treatment of STEC-HUS is merely symptomatic and
eculizumab is not indicated for the treatment of STEC-HUS
[13, 14]. This underlines the importance of discriminating
between these types of HUS and limiting the unnecessary
use of eculizumab in STEC-HUS.
With this retrospective study, the clinical utility of the
glyco-iELISA compared to LPS-ELISA is accessed in two
cohorts. The first cohort comprises pediatric patients of a sin-
gle center with strong clinical suspicion of STEC-HUS, of
which all clinical data were gathered. The second cohort is
nationwide cohort of patients with signs indicative of TMA
of which STEC infection could be a potential cause.
Methods
A retrospective single-center pilot study was performed,
which included all pediatric patients who presented with a
clinical pattern of STEC-HUS between 1990 and 2014 to
the Pediatric Nephrology department of the Radboud
University Medical Center (Radboudumc) Amalia
Children’s Hospital. A clinical pattern of STEC-HUS was
defined as signs of a TMA, together with (bloody) diarrhea
or a family member with diarrhea. Signs of TMA were clas-
sified as signs indicative of hemolysis (low hemoglobin, ele-
vated LDH, depleted haptoglobin), acute renal injury, and
thrombocytopenia of < 150 × 109/l. Fever at presentation
was defined as body temperature above 38.2 °C as reported
by patients and/or parents. Anuria was defined as a urine pro-
duction below 0.1 ml/kg/h for at least 12 h. The estimated
glomerular filtration rate (eGFR) was calculated with the
Schwartz formula (k 36.5) [16]. According to the pediatric
Risk, Injury, Failure, Loss, End-stage renal disease
(pRIFLE) criteria, renal injury is defined as an increased cre-
atinine ×2 or decreased eGFR > 50%. Renal failure was de-
fined as an increased creatinine ×3 or decreased eGFR > 75%
[17]. The first day of illness was defined as the first day of
diarrhea reported by the patient and/or parents. All available
clinical and diagnostic data of these patients were collected in
the STEC-HUS registry—an online web-based database.
Residual material (serum) received during standard care was
used to detect IgM antibodies against serotype O157 with
LPS-ELISA aswell as glyco-iELISA. This single-center study
comprised the same patient cohort as previously described by
Wijnsma et al. [6].
Subsequently, the diagnostic value of glyco-iELISA in
STEC-HUS diagnosis was evaluated in a retrospective nation-
wide study. Since Radboudumc Amalia Children’s Hospital is
the center of expertise for HUS patients in the Netherlands,
LPS-ELISA for serotype O157 is only performed at the
Translational Metabolic Laboratory in Radboudumc. This
study included all residual sera samples from both pediatric
and adult patients with signs of TMA. Of note, TMA was
defined as thrombocytopenia, hemolytic anemia, and organ
damage; yet, the underlying disease leading to the develop-
ment of TMAwas unknown at the time of sampling. Samples
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from these patients were sent to Radboudumc Amalia
Children’s Hospital, between 2007 and 2014, from other uni-
versity medical centers throughout the Netherlands for LPS-
ELISA to diagnose or exclude STEC-HUS. All these residual
sera samples were additionally tested for the presence of IgM
antibodies against STEC O157 with glyco-iELISA. In addi-
tion, serum of 19 healthy adult controls was collected to de-
termine the specificity of the assays and determine cutoff
values.
This study does not fall within the remit of the Medical
Research Involving Human Subjects Act (WMO). The study
has been reviewed by the ethics committee on the basis of the
Dutch Code of conduct for health research, the Dutch Code of
conduct for responsible use, the Dutch Personal Data
Protection Act and the Medical Treatment Agreement Act.
The ethics committee has passed a positive judgment on the
study (2017-3490).
Index test: glyco-iELISA
The glyco-iELISAwas performed as described by Melli et al.
[11]. In brief, a microtiter plate was coated with recombinant
glycoproteins (O157-AcrA) and incubated overnight at 4 °C.
The following day, the plate was blocked with PBS-0.1%
Tween 20 (PBST) + 0.5% skimmed milk for 1 h at room
temperature (RT). Subsequently, diluted human serum sam-
ples (dilution of 1:800) were added and incubated for 1 h at
RT. Next, the plate was washed and goat anti-human IgM
(HRP-conjugated) antibody added and incubated for 1 h at
RT. Hereafter, 3,3′,5,5′-tetramethylbenzidine (TMB, Sigma
Aldrich) reagent as a substrate for HRP was added. Finally,
the enzymatic reaction was stopped with 0.16 M sulfuric acid
(H2SO4) and the absorbance measured at 450 nm (nm) with a
spectrometer-based microtiter plate reader. Samples were con-
sidered positive when an optical density (OD) above 0.5 was
observed.
Cross-reactivity was tested by adding sera from
predetermined positive patients with various STEC serotype in-
fections (resp. O26, O55, O103, O111, O145) together with
predetermined negative patients, to an ELISA plate coated with
glycoprotein serotype O157.
To study the effect of multiple freeze-thaw cycles on the
patient blood samples, we freeze-thawed different previously
determined positive samples, taken from three STEC-HUS
patients, on 5 subsequent days. This resulted in samples of 1
up to 5 freeze-thaw cycles for each patient.
Reference standard: fecal diagnostics and LPS-ELISA
Feces and serum from suspected STEC-HUS patients were
collected as soon as possible after admission to the hospital.
In cases where feces could not be obtained, a rectal swab was
done. Serum was received from all patients during standard
care and stored at − 80 °C until analysis. Fecal diagnostics and
LPS-ELISA were performed as previously described [6].
Fecal diagnostics were considered positive when either PCR
for Stx 1 and/or 2, the presence of fecal free Stx by using the
verocell assay, or the fecal culture (using Sorbitol MacConkey
agar plate) was positive for STEC. In the case of dubious test
results, we considered the result as negative. After 2007, it
became possible to send the STEC strains, isolated from the
feces, to the Dutch National Institute for Public Health and
Environment (RIVM) for further determination of the sero-
type, both O157 and non-O157. For LPS-ELISA, patients
were considered positive when an optical density (OD) above
0.8 was observed. This cutoff was previously determined in
close collaboration with Chart et al. [18].
Assay characteristics
The response of both LPS-ELISA as glyco-iELISA was
established by determining the lowest signal to detect a posi-
tive sample. In each setup of the plate, one previously deter-
mined positive and negative patient samples for the presence
of antibodies against O157 antigens were diluted to different
concentrations. Positive/negative ratios (P/N ratios) were cal-
culated by dividing the OD obtained for each specific concen-
tration. Subsequently, the coating antigen concentration was
also taken into account when the sensitivity of the assays was
compared.
Statistics
For each assay, the mean, standard deviation (SD), and coef-
ficient of variation (CV) were calculated. Furthermore, for the
glyco-iELISA assays with patient screening, cutoff values
were established using the following formula: mean control
sera OD ± 2 SD.
Clinical values were expressed as valid percentages for
categorical variables, and as the mean and SD, or median
and 25–75% interquartile range (IQR) for continuous vari-
ables, as appropriate. The chi-square test was performed to
compare categorical data. p values of < 0.05 were considered
statistically significant. All graphs were created using
GraphPad Prism software, version 5. For statistical analyses,
SPSS software (version 22.0) was used.
Results
Patient characteristics
As previously published, during the period between 1990 and
2014, 65 patients with a clinical pattern of STEC-HUS presented
in the Pediatric NephrologyDepartment of RadboudumcAmalia
Children’s Hospital. Unfortunately, of the 65 patients, 14 patients
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had to be excluded from this analysis due the absence of residual
material to test glyco-iELISA. The patient characteristics of the
51 STEC-HUS patients are described in Table 1. One patient
with a highly severe presentation of STEC-HUS died due to a
systemic inflammatory response syndrome. STEC infection was
proven with both fecal diagnostics and serology.
During the period between 1990 and 2017, a total of 264
serum samples from patients with acute TMAwere sent to the
laboratory of the HUS center of expertise at the
Radboudumc Amalia Children’s Hospital. Of the 264
serum samples of this nationwide cohort, 212 samples
were collected from 206 patients with TMA and 52
samples from 50 relatives of these patients. The median
(range) age of the patients was 6 (0–73) years. The
majority of the relatives were parents (n = 42), 5 sib-
lings were tested, and 3 grandparents. Unfortunately,
no clinical data were available from these patients as
the samples were obtained from different hospitals in
the Netherlands.
Assay characteristics of glyco-iELISA
Since some samples were stored for quite some years, we
accessed the stability of antibodies in our samples.
However, up to 5 freeze-thaw cycles did not seem to
have an effect on the OD values determined by glyco-
iELISA (data not shown). Furthermore, in contrary to
LPS-ELISA, glyco-iELISA shows low intra- and inter-
assay variation (CV < 20%).
The discrimination capacity to detect positive and negative
signals of LPS-ELISA and glyco-iELISAwas determined for
serological antibodies against O157 antigen and compared to
each other (Fig. 1). Higher positive/negative (P/N) ratios were
obtained with the glyco-iELISA, especially when using
1250 ng/ml glycoprotein with 800 times serum dilution (P/N
ratio of 6.6) compared to LPS-ELISA. Furthermore, no cross-
reactivity was observed for STEC serotypes O26, O111,
O145, O103, and O55 antigens in the glyco-iELISA (Fig. 2).
Sensitivity of glyco-iELISA
In total, 51 STEC-HUS patients with serology and clinical
data were available and included in the analysis. Since the
PCR for Stx genes was introduced in our hospital in 2011, it
was only performed in 12 of the patients. In total, 9 patients
had a proven STEC infection based on PCR for Stx, of which
7 were also confirmed with glyco-iELISA O157. The remain-
ing two patients had a proven STEC infection with serotypes
O55 and O26, explaining the negative glyco-iELISA result
(see Table 2).
Furthermore, in 17 patients, further determination of STEC
serotype took place based on fecal diagnostics and yielded 14
STEC infections with isolated strain serotype O157. All these
patients also had serology for O157 tested with glyco-iELISA.
This compared to serology tested by LPS-iELISA in which 2
patients tested negative.
Table 1 Characteristics of pediatric patients with STEC-HUS in a
single-center cohort
Parameter All patients
(n = 51)
Male 47%
Age of onset in months 36 (23–65)
Symptoms at presentation
Fevera 22%
Diarrhea, totalb 96%
Of which bloody 78%
Anuria (defined as < 0.1 ml/kg/h) 57%
Blood pressure
< p95 44%
> p95 56%
Neurological involvement 12% (n = 6)
Convulsions 8% (n = 4)
Coma 0%
Miscellaneousc 10% (n = 5)
Pancreas involvement 4%
Biochemical evaluation at presentation (reference range)
Hemoglobin (mmol/l) (6.0–9.0) 5.3 (4.0–6.3)
White blood cells (×109/l) (5.0–13.0) 14.5 (10.97–22.5)
Platelet count (×109/l) (210–430) 45 (32–76)
Haptoglobin (g/l) (0.3–1.6) < 0.08 (0.04–0.10)
LDH (U/l) (<250) 3929 (2525–5817)
Creatinine (μmol/l) (strongly depending
age and body mass)
307 (190.5–430)
eGFR (ml/min.1.73m2)d (> 90) 13 (8–23)
Treatment
Dialysis 65%
Duration of dialysis in days 10 (7–14)
Erythrocytes transfusion 92%
≥ 3 transfusions 20%
Categorical values are expressed as percentage of total, and for continu-
ous variables, the median with interquartile range (IQR) is expressed.
Neurological involvement included areflexia, coma, epilepsy, and signs
indicative of encephalopathy (decreased consciousness, abnormal behav-
ior, amnesia, disorientation for time/person/place, disturbed speak, aprax-
ia, hyperreflexia). P95: percentile for age and height [19]
a Fever, defined as body temperature above 38.2 °C, was reported by
patients and/or parents
b Of note, we report two patients suspected of STEC-HUS without diar-
rhea. In one patient, STEC infection could be established by both fecal
diagnostics (with rectal swab) as well as serology. In the second patient,
serology for STEC O157 was negative and PCR was repeatedly reported
as dubious. STEC-HUS seemed very likely, also in the light of good
clinical recovery with minimal sequelae (mild proteinuria) and no recur-
rence after 6 years
c Either in combination with convulsion or as solo presentation. Other
neurological symptoms reported were decreased consciousness (n = 3),
ataxia (n = 1), and apathy (n = 1)
dAll patients had signs indicative of renal injury according to the pRIFLE
criteria. In total, 46 patients had renal failure based on the pRIFLE criteria
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Time window to perform glyco-iELISA
In 8 patients of our single-center cohort, serum was collected
at various time points after the onset of diarrhea. These sam-
ples were used to examine the production of serum IgM anti-
bodies (tested with glyco-iELISA) during the disease course
of STEC-HUS (Fig. 3). A clear positive result for STECO157
was already observed 1 day after the start of diarrhea.
However, there is a strong variation between individuals.
Patient 3 had no antibodies against STEC O157 on day 1;
however, when tested on day 8 and 14, antibodies could be
detected. Patient 4 (with negative serology on day 1) had a
positive antibody response up to 23 days, after which the
signal dropped significantly. Patient 5 had persisting antibod-
ies until 51 days after the start of diarrhea.
Single-center cohort of STEC-HUS patients
Of the 51 STEC-HUS patients, 22 (43%) had a positive fecal
diagnosis for STEC, 33 (65%) had positive serology based on
LPS-ELISA against O157, and 40 (78%) had positive serolo-
gy based on glyco-iELISA (see Table 3 and Fig. 4). In total, 3
patients appeared positive with O157 LPS-ELISA, whereas
they were negative with glyco-iELISA. In 2 of these patients,
fecal diagnostics revealed STEC infection with serotype O26
and O55, which explains the negative glyco-iELISA result,
indicating a false-positive result (due to cross-reactivity) in
the LPS-ELISA. In the third patient, the STEC strain was
not further determined. Overall, the glyco-iELISA yielded
10 patients that were previously negative with LPS-ELISA.
In conclusion, glyco-iELISA yielded significantly more pa-
tients positive for the presence of STEC when compared to
fecal diagnostics (p < 0.0001) and LPS-ELISA (p = 0.04).
Moreover, when combining fecal diagnostics with glyco-
iELISA, STEC was detected in significantly more patients
(86%, p = 0.03) than when combined with LPS-ELISA
(73%).
Nationwide cohort of patients with TMA
The 264 serum samples of the nationwide cohort of patients
with TMA sent in for STEC O157 serology were tested with
both LPS-ELISA and glyco-iELISA and the outcome differed
significantly (p < 0.0001). When the 212 samples from the
patients with TMA suspicion were tested using LPS-ELISA,
48 (23%) samples were diagnosed as positive and 164 (77%)
as negative (Table 4). When tested with glyco-iELISA, 60
(38%) samples of patients with TMA were confirmative for
STEC O157 infection.
Subsequently, the 52 serum samples from the relatives of
patients with TMAwere tested with LPS and glyco-iELISA as
well (Table 4). Interestingly, 10 were positive with the glyco-
iELISA indicative of STEC infection. Of these relatives, in all
but one, the index patient tested positive for STEC infection as
well. In this patient, mother tested positive for STEC O157;
however, the patients tested negative with both glyco-iELISA,
as well as LPS-ELISA.
In total, of all patients with clinical suspicion of STEC-
HUS (n = 206, with 212 samples), 56 (27%) patients tested
positive for STEC O157 infection with glyco-iELISA.
Overall, using the glyco-iELISA, 19 (7.2%) patients
with TMA that were previously diagnosed as negative
with LPS-ELISA could be diagnosed as STEC O157
positive (p < 0.001).
Fig. 1 Response of LPS-ELISA versus glyco-iELISA. The response of
both assays was assessed by determining the lowest signal at which a
positive sample could still be detected for both LPS-ELISA as glyco-
iELISA for STEC serotype O157. One previously determined positive
and negative samples were each diluted with different concentrations.
Positive/negative ratios were calculated by dividing the optical density
obtained for each specific concentration. Subsequently, the coating anti-
gen concentration was also taken into account when the accuracy of the
assays was compared. LPS lipopolysaccharide, P/N positive negative
ratio
Fig. 2 No cross-reactivity was observed with the glyco-iELISA for dif-
ferent STEC serotypes. No cross-reactivitywith different STEC serotypes
was observed with the O157 glyco-iELISA. After coating with glycopro-
tein O157, pooled sera of various healthy negative controls (NC) and 4
separate NC, together with sera of patients (P) with predetermined STEC
infection with respective STEC serotypes O26, O55, O103, O111, O145,
and O157 were added. Every bar represents one patient with STEC-HUS
due to the serotype as indicated. The dotted bar represents the cutoff value
of 0.5 optimal density (OD). Only the patients with STEC-HUS with
serotype O157 were determined as positive, indicating no cross-reactivity
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Discussion
Differentiation between different etiologies of HUS is highly
important regarding treatment and outcome. Since aHUS is a
diagnosis per exclusionem, proving proof of STEC infection
in a Btypical^ STEC-HUS is essential. However, fecal diag-
nostics, the gold standard to diagnose STEC-HUS, have some
major drawbacks, most importantly due to the natural course
of disease and low inoculums. Serological diagnostics, like
using anti-O157 LPS antibodies, have proven its added value
to fecal diagnostics, although this diagnostic assay has a dif-
ferent bottleneck: potential cross-reactivity and limited sensi-
tivity. Here, we show that the novel glyco-iELISA to detect
anti-O157 antibodies is highly sensitive and specific, and its
use in STEC diagnostics leads to more patients displaying
positive STEC-O157 infections causing HUS. More
importantly, using glyco-iELISA STEC O157-infections
could be detected for a long period of time after start of the
disease.
With this study, the clinical utility of the glyco-iELISAwas
assessed. Melli et al. were the first to publish their findings
regarding this novel glyco-iELISA using bacterial-engineered
glycoproteins for serotype O157, O145, and O121 [11]. In a
cohort of 71 samples taken from pediatric patients (compris-
ing both STEC-positive patients and STEC-negative patients
with clinical suspicion of STEC-HUS), they showed that the
glyco-iELISAwas highly sensitive and specific. Furthermore,
no cross-reactivity between the previous serotypes was ob-
served, confirming our results. The same group published a
second article in 2017 by Castillo et al. where they further
investigated cross-reactivity between different STEC sero-
types (resp. O111, O103, O45, O26, O104) and other gram-
negative bacteria (salmonella, Brucella abortus, Yersinia
enterocolitica O9). Again, no cross-reactivity was observed
[8]. This is in contrast to LPS-ELISA, where clear cross-
reactivity between different serotypes has been reported [7].
Overall, with access to the glycoproteins, glyco-iELISA is an
easily implemented and performed assay with stable results.
Ideally, one would calculate sensitivity (proportion of pa-
tients with STEC-HUS in which the glyco-iELISA is positive)
and specificity (proportion of patients with TMA caused by
other conditions than STEC in which the glyco-iELISA re-
mains negative) for an assay like glyco-iELISA. However,
various problems arise when attempting to do so. The most
prominent one has to dowith the accuracy of the gold standard
to diagnose STEC-HUS. Since fecal diagnostics are not suffi-
cient to diagnose all STEC-HUS patients, no optimal gold
standard is present to calculate sensitivity and specificity.
Moreover, serology should not replace fecal diagnostics, but
should be used in addition, to complement microbial diagnos-
tics and broaden the time window to detect STEC. Hence,
accurate estimation of sensitivity and specificity is not
Table 2 Comparison between
fecal diagnostics and glyco-
iELISA for antibodies against
STEC O157 antigen in patients
with STEC-HUS in single-center
cohort
Assays Positive glyco-
iELISA O157
Negative glyco-
ELISA O157
Total number
of patients
Positive fecal diagnostics* 18 4 22
Feces culture 15 2 17
Free fecal toxin (verocell assay) 8 3 11
PCR 7 2 9
Negative fecal diagnostics 22 7 29
Feces culture 9 8 17
Free fecal toxin (verocell assay) 11 5 16
PCR 2 1 3
Total number of patients 40 11 51
*Patients can be positive for each fecal diagnostic assay separate as well as all combined
PCR polymerase chain reaction
Fig. 3 Time window to perform glyco-iELISA to detect IgM against
STEC O157. From 8 STEC-HUS patients, multiple serum samples col-
lected after the onset of diarrhea on different days during the course of
their disease were tested using glyco-iELISA for the presence of antibod-
ies against serotype O157. The dotted line represents the cutoff value of
0.5 optical density (OD) after which samples are categorized as positive
for antibodies against serotype O157 in the glyco-iELISA
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feasible. However, in our cohort, in contrast to LPS-iELISA,
all patients with proven O157 in the feces were positive with
glyco-iELISA, indicating high sensitivity (100% in our co-
hort). Furthermore, in patients with proven STEC infection
with a non-O157 serotype, glyco-iELISA for O157 remained
negative, again in contrast to LPS-ELISA for O157, indicating
high specificity.
As stated previously, cross-reactivity between LPS of dif-
ferent gram-negative bacteria is a known problem due to the
conserved lipid A part of the LPS molecule. We hypothesized
that cross-reactivity, as observed in LPS-based ELISAs, can
present as a false-positive test result in the O157 LPS-ELISA.
This may be due to the presence of antibodies against other
non-O157 STEC serotypes or even other gram-negative bac-
teria, which to some extent are able to bind to the lipid A part
of STEC serotypes. Interestingly, using the highly specific and
sensitive glyco-iELISA, we observed an increase in the detec-
tion of STEC infections, rather than a decrease due to false-
positive results. Different explanations could explain this
better performance. Primarily, STEC serotype O157 is still a
highly prevalent serotype causing HUS in the Netherlands.
Therefore, not much cross-reactivity could be found, since
non-O157 serotypes causing HUS are less common.
Furthermore, as shown in our single-center cohort, the
glyco-iELISA is able to detect all patients with confirmed
O157 serotype in the feces and remains negative in patients
with a confirmed infection with other serotypes. Hence, the
negative result obtained with the glyco-iELISA seemed accu-
rate, indicating that the LPS-ELISA is probably a false-
positive result due to cross-reactivity between different
STEC serotypes, as was found to be the case in two of our
patients. Other methods to detect serology have been reported,
such as line blot immunoassay and immunoblotting, however,
all use purified LPS to detect antibodies; hence, potential
cross-reactivity remains present [7].
Interestingly, of the 52 samples of relatives without clinical
HUS features, 10 (19.2%) had antibodies detected with the
glyco-iELISA, indicating STEC O157 transmission person-
to-person or intake of the same contaminated food. In all ex-
cept one, the index patient tested positive for STEC infection.
Although we have no clinical information about relatives in
our study, we could show that family members of STEC-HUS
patients with no or mild signs of gastrointestinal infection can
develop antibodies against O157. These results are in line with
Ludwig et al. who reported that 17% of the household contacts
(symptomatic as well as asymptomatic) of STEC-HUS pa-
tients had LPS IgM antibodies against STEC serotype O157
[20]. The exact rate of IgM antibodies against STEC serotypes
in the healthy population is still unknown. However, to ex-
clude potential false-positive results, one could consider only
testing for the presence of IgM and not IgG, since IgG can be
present for years after infection. Yet, we would recommend
testing family members of patients with STEC (with fecal
diagnostics and serology), especially in patients who tested
negative for STEC infection. By providing proof of STEC
infection in household contact, the diagnosis of STEC-HUS
in the index patient despite negative diagnostics becomes
more likely.
We found IgMantibodies against STECO157 up to 55 days
after onset of the disease. These results are in line with previ-
ous reported kinetics of IgM (LPS-based assay) against STEC
Table 3 Comparison between
LPS-ELISA and glyco-iELISA
for antibodies against STEC
O157 antigen in single-center
cohort
Assays Positive glyco-iELISA
O157
Negative glyco-iELISA
O157
Total
Positive LPS-ELISA O157 30 3* 33
Negative LPS-ELISA O157 10 8 18
Total amount of STEC-HUS patients 40 11 51
HUS hemolytic uremic syndrome, LPS lipopolysaccharide, STEC Shiga toxin–producing Escherichia coli
*Fecal diagnostics revealed O26 strain (n = 1), O55 strain (n = 1), and no further determination of serotype was
performed (n = 1)
Fig. 4 Proportion of pediatric HUS patients from single-center cohort
tested positive for STEC infection with different diagnostic tools. The
proportion of STEC-HUS patients in the single-center cohort per diag-
nostic test is described, given in percentages of the total 51 patients. The
proportion of respectively positive (white bar) and negative patients
(black bar) are depicted for fecal diagnostics (STEC detection by stool
culture, free fecal Shiga toxin by verocell assay, PCR for Shiga toxin
genes), LPS-ELISA, and glyco-iELISA for STEC serotype O157 (respec-
tively LPS-O157 and Glyco-O157) and combined. When glyco-iELISA
was combined with fecal diagnostics, the percentage of positive STEC
patients increased up to 86%. fecal diagnostics, lipopolysaccharide,
STEC Shiga toxin–producing Escherichia coli
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by Chart et al. [21]. Hence, in contrast to fecal diagnostics in
which the isolation rate declines quickly after the initial symp-
toms (within 1 week), serology (both LPS- and glyco-
iELISA) broadens the time window to diagnose STEC infec-
tions. Furthermore, when serum is collected too early in the
course of the disease, serology could be negative due to as yet
incomplete seroconversion, as was the case in two of our
patients. In case of a negative serology result tested in serum
collected within 7 days after disease onset, the advice would
be to collect and test serum again after 7 days for a re-evalu-
ation. As described previously, the added value of serology
increases even more 7 days or more after the start of the
symptoms [6].
Limitations of this study are the retrospective nature and
the lack of clinical data of the national TMA cohort.
Serological detection of STEC infection by detection of anti-
O157 antibodies in serum is advised in the national guideline
of diagnostic workup for TMA at presentation. Presumably,
some patients in the national cohort had a different diagnosis
that not only comprised STEC-HUS, but also aHUS or other
causes of TMA. Concerning the single-center cohort of pedi-
atric patients, STEC infection could not be detected in seven
patients with clinical suspicion of HUS. Yet, aHUS as a diag-
nosis is highly unlikely regarding the clinical presentation
with bloody diarrhea in all seven patients. Although aHUS
can present in 30% of cases with gastrointestinal infection,
bloody diarrhea is seldom reported in aHUS. Also, follow-
up data showed no disease recurrence, making aHUS highly
unlikely in this single-center cohort. In three patients, genetic
analysis was performed and showed no pathogenic mutations
in complement genes associated with aHUS. Furthermore, in
most patients, serology was only tested at one time point.
Seroconversion takes 3–5 days; hence, patients whowere seen
early in the course of disease could be false negative.
Furthermore, we focused on the still most prevalent STEC
serotype causing HUS in our country, O157; however, nowa-
days, non-O157 serotypes are increasingly detected as a cause
of HUS. The relatively high number of patients with STEC
O157 infection in our cohort could be explained by the sub-
stantial number of STEC-HUS patients who were included
from the late 1990s, when serotype O157 was, as it still is,
the main serotype to cause STEC-HUS. Nowadays, non-O157
serotypes causing HUS are increasingly detected, partly ex-
plained due to new and improved diagnostic assays. In this
study, non-O157 STEC serotypes were not detected [2, 4]. It
would be very worthwhile in the near future to examine the
14% of clinical STEC-HUS patients who were negative in
fecal and serological diagnostics for other STEC serotypes
with glyco-iELISA. Hence, future plans are to expand
glyco-iELISA to detect multiple serotypes. Melli et al. have
already described the use of glyco-iELISA for STEC sero-
types O145 and O121, with comparable results regarding ab-
sence of cross-reactivity and sensitivity of the assays [11].
Furthermore, it is highly important to differentiate between
STEC-HUS and aHUS as soon as possible, to start appropriate
treatment. Since the current glyco-iELISA takes at least 24 h
to perform, future studies should focus on improving this as-
say for bedside use. For example, by using lateral flow tech-
nology, one could develop a point of care test for patients
presenting with TMA.
In conclusion, serological assays for STEC O-antigens
have a place in the diagnostic workup plan of patients with
TMA. Moreover, since aHUS is a diagnosis per exclusionem,
it is highly important to diagnose STEC-HUS. Therefore, we
advocate always combining fecal diagnostics together with
serological diagnostics to achieve optimal diagnostics and pre-
vent unnecessary use of the highly expensive orphan drug
eculizumab. The optimal assay to determine serological anti-
bodies against STEC serotype O157 is the glyco-iELISA.
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Table 4 Comparison between
LPS-ELISA and glyco-iELISA in
nationwide cohort of patients with
thrombotic microangiopathy
(TMA) of unknown etiology
Assays Positive
glyco-
iELISA O157
Negative
glyco-
iELISA O157
Total
Total number of patients/relatives with positive LPS-ELISA O157 51 0 51
Patients 48 0 48
Relatives 3 0 3
Total number of patients/relatives with negative LPS-ELISA O157 19 194 213
Patients 12 152 164
Relatives 7 42 49
Total number of patients/relatives 70 194 264
HUS hemolytic uremic syndrome, LPS lipopolysaccharide, STEC Shiga toxin–producing Escherichia coli
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